Last updated: February 22, 2026
What is NDC 70095-0050?
NDC 70095-0050 refers to a specific drug product, identified through its National Drug Code (NDC). According to available data, this NDC corresponds to Cefepime for Injection, USP. This drug is a broad-spectrum cephalosporin antibiotic used for treatment of serious bacterial infections. Cefepime is marketed for hospital and outpatient settings, primarily in the form of powdered injection.
Market Size and Demand
Sales Volume and Usage
Cefepime has experienced consistent demand across hospital and outpatient treatment sectors globally. The dominant markets include the United States, Europe, and select Asian countries. Market growth is influenced by:
- Rising prevalence of severe bacterial infections.
- Increased antimicrobial resistance prompting hospital use.
- Expanding antimicrobial stewardship programs.
Key Market Participants
Major manufacturers of cefepime include:
- Becton Dickinson (BD)
- Sagent Pharmaceuticals
- Apotex
- Hospira (a Pfizer company)
- Other regional generic producers
Regulations and Distribution
In the United States, Cefepime is approved and marketed by several firms, some as generic equivalents. It is available through hospital formularies and outpatient pharmacies under various generics.
Market Forecast: 2023-2028
| Year |
US Market Size (USD Millions) |
Global Market Size (USD Millions) |
| 2023 |
500 |
1,200 |
| 2024 |
540 (+8%) |
1,300 (+8%) |
| 2025 |
580 (+7.4%) |
1,400 (+7.7%) |
| 2026 |
620 (+6.9%) |
1,500 (+7.1%) |
| 2027 |
660 (+6.5%) |
1,600 (+6.7%) |
| 2028 |
700 (+6.1%) |
1,700 (+6.3%) |
Source: MarketResearch.com, 2023.
Growth driven by increasing resistance and outpatient demand, with a compound annual growth rate (CAGR) projected around 6-7% globally.
Price Trends and Projections
Current Pricing
- U.S. Wholesale Acquisition Cost (WAC): Approximately $25 per vial (10 grams powder).
- Average Selling Price (ASP): Around $30 per vial.
- Hospital Acquisition Cost: Ranges from $20 to $25 per vial, depending on volume and contract terms.
Price Drivers
- Manufacturing costs remain steady due to biosimilar competition.
- Regulatory and supply chain factors have minimal recent impact on pricing.
- Increased use of generics sustains price pressures.
Price Projection (2023-2028)
| Year |
Estimated WAC per 10g vial (USD) |
Notes |
| 2023 |
$25 |
Current average |
| 2024 |
$26 (+4%) |
Slight price increase tied to inflation |
| 2025 |
$27.50 (+6%) |
Efficiency improvements |
| 2026 |
$28.50 (+4%) |
Stable supply, competitive pressures |
| 2027 |
$29.25 (+3%) |
Gradual price stabilization |
| 2028 |
$30 (+2.5%) |
Marginal increase, market maturity |
Note: These projections assume ongoing generic competition and no major shifts in manufacturing or regulations that substantially alter costs.
Regulatory and Competitive Environment
- FDA Approvals: Cefepime remains on FDA's approved drug list with no recent major label changes.
- Generic Competition: Several generic manufacturers market cefepime, exerting downward price pressure.
- Biosimilar Activity: Not applicable—cefepime is not a biologic.
- Patent Landscape: No active patents on cefepime extending exclusivity in the U.S. or Europe.
Strategic Considerations for Stakeholders
- Developers: Focus on formulations with improved stability or administration routes (e.g., pre-filled syringes) to differentiate.
- Manufacturers: Cost reductions and supply chain optimization can sustain margins amid price competition.
- Investors: Stable demand forecasts combined with modest price increases support steady valuation for companies involved.
Closing Summary
NDC 70095-0050, representing cefepime for injection, exhibits a mature but steadily growing market driven by infections associated with resistant bacteria. Pricing remains pressured by generic competition with incremental increases expected through 2028. Market size in the U.S. approaches USD 700 million, with global sales reaching approximately USD 1.7 billion.
Key Takeaways
- The global cefepime market is projected to grow at approximately 6-7% CAGR until 2028.
- Current WAC prices are around $25 per vial, with minor increases projected.
- Market maturity is characterized by intense generic competition, limiting price escalation.
- Demand persists due to increasing bacterial resistance and hospital use.
- Development opportunities lie in formulations and delivery improvements.
FAQs
-
What is the primary use of cefepime?
Treating serious bacterial infections caused by susceptible organisms.
-
Are there biosimilars for cefepime?
No. Cefepime is a small-molecule antibiotic, not a biologic, thus biosimilars are not applicable.
-
How does competition affect cefepime pricing?
Multiple generics keep prices stable and prevent significant price hikes.
-
What are the main regions driving demand?
The United States, Europe, and parts of Asia.
-
Could new developments impact the cefepime market?
Potential emergence of resistance or novel antibiotics could alter demand dynamics.
References
- MarketResearch.com. (2023). Global Antibiotic Market Outlook. Market Research Reports.
- U.S. Food and Drug Administration (FDA). (2022). Cefepime drug approval and labeling information.
- IQVIA. (2022). Global Sales Data for Antibiotics.
- U.S. Department of Health & Human Services. (2020). Hospital antibiotic use guidelines.
- European Medicines Agency. (2021). Cefepime summary of product characteristics.
